Clinical Performance and Management Outcomes with the DecisionDx-UM Gene Expression Profile Test in a Prospective Multicenter Study

<div>Metastasis-free survival (MFS) rates for CLEAR registry patients. Kaplan-Meier analysis of MFS for 70 patients enrolled in the CLEAR uveal melanoma study. Class 1 patients had a 3-year MFS rate of 100% versus 63% for Class 2 patients; the median rate of metastasis was 3.78 years for Class 2 patients but not reached for Class 1 patients.</div>

Journal of Oncology

fig1

Figure 1

Figure 1: Clinical Performance and Management Outcomes with the DecisionDx-UM Gene Expression Profile Test in a Prospective Multicenter Study 